Associated Papers
Characteristics and pharmacological responsiveness in hiPSC models of inherited cardiomyopathy.
Gerritse M et al.
Pharmacology & Therapeutics, 2025
Experimental Models of Hypertrophic Cardiomyopathy: A Systematic Review.
van den Dolder FW et al.
Jacc. Basic to Translational Science, 2025
Generation of induced pluripotent stem cells from an individual with early onset and severe hypertrophic cardiomyopathy linked to MYBPC3: c.772G > A mutation.
Ribeiro M et al.
Human Cell, 2024
Advances in Hypertrophic Cardiomyopathy Disease Modelling Using hiPSC-Derived Cardiomyocytes.
Dababneh S et al.
The Canadian Journal of Cardiology, 2024
Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline.
Tamargo J et al.
Expert Opinion on Investigational Drugs, 2022
Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy.
Riaz M et al.
Circulation, 2022
Cell cycle defects underlie childhood-onset cardiomyopathy associated with Noonan syndrome.
Meier AB et al.
Iscience, 2022
Ventricular arrhythmia and sudden cardiac death in hypertrophic cardiomyopathy: From bench to bedside.
Shen H et al.
Frontiers in Cardiovascular Medicine, 2022
Ion Channel Impairment and Myofilament Ca2+ Sensitization: Two Parallel Mechanisms Underlying Arrhythmogenesis in Hypertrophic Cardiomyopathy.
Santini L et al.
Cells, 2021
Preventative therapeutic approaches for hypertrophic cardiomyopathy.
Solomon T et al.
The Journal of Physiology, 2021
Genetic Cardiomyopathies: The Lesson Learned from hiPSCs.
My I et al.
Journal of Clinical Medicine, 2021
Uncovering Inherited Cardiomyopathy With Human Induced Pluripotent Stem Cells.
Jiang X et al.
Frontiers in Cell and Developmental Biology, 2021
Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening.
Ovics P et al.
International Journal of Molecular Sciences, 2020
Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
Bhagwan JR et al.
Journal of Molecular and Cellular Cardiology, 2020
Modelling sarcomeric cardiomyopathies with human cardiomyocytes derived from induced pluripotent stem cells.
Sewanan LR et al.
The Journal of Physiology, 2020
Human Induced Pluripotent Stem-Cell-Derived Cardiomyocytes as Models for Genetic Cardiomyopathies.
Brodehl A et al.
International Journal of Molecular Sciences, 2019
Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes-a systematic review.
Eschenhagen T et al.
Pflugers Archiv : European Journal of Physiology, 2019
Applying Patient-Specific Induced Pluripotent Stem Cells to Create a Model of Hypertrophic Cardiomyopathy.
Dementyeva EV et al.
Biochemistry. Biokhimiia, 2019
Concise Review: The Current State of Human In Vitro Cardiac Disease Modeling: A Focus on Gene Editing and Tissue Engineering.
Hoes MF et al.
Stem Cells Translational Medicine, 2019
Phenotypic Screening Using Patient-Derived Induced Pluripotent Stem Cells Identified Pyr3 as a Candidate Compound for the Treatment of Infantile Hypertrophic Cardiomyopathy.
Sakai T et al.
International Heart Journal, 2018
Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient iPSC-Derived Cardiomyocytes with MT-RNR2 Mutation.
Li S et al.
Stem Cell Reports, 2018
Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes.
Giacomelli E et al.
Cellular and Molecular Life Sciences : Cmls, 2017
Untangling the Biology of Genetic Cardiomyopathies with Pluripotent Stem Cell Disease Models.
Buikema JW et al.
Current Cardiology Reports, 2017
Induced pluripotent stem cells in the inherited cardiomyopathies: From disease mechanisms to novel therapies.
Ross SB et al.
Trends in Cardiovascular Medicine, 2016
Mutation-Specific Phenotypes in hiPSC-Derived Cardiomyocytes Carrying Either Myosin-Binding Protein C Or α-Tropomyosin Mutation for Hypertrophic Cardiomyopathy.
Ojala M et al.
Stem Cells International, 2016
Recent Advances in the Molecular Genetics of Familial Hypertrophic Cardiomyopathy in South Asian Descendants.
Kraker J et al.
Frontiers in Physiology, 2016
Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.
Han L et al.
Cardiovascular Research, 2014